Navigation Links
Mayo Clinic Study Shows Drug Could Effectively Treat, Prevent the Spread of Breast Cancer
Date:11/1/2007

riments in mouse models to determine whether 2ME2 would be an effective drug against breast cancer. The results are promising. Researchers described 2ME2 as an "attractive candidate for controlling tumor growth, metastasis to bone and bone disorders," such as osteolysis caused by the spread of breast cancer to bone. Based on the study findings, the researchers propose that 2ME2 be used as a therapeutic agent to target primary tumors, metastasis to bone and tumor-induced osteolysis.

There are few effective treatments for advanced breast cancer, but in this case, the study authors feel that 2ME2 has the potential to improve the prognosis of patients with advanced breast cancer.

"Targeting metastatic tumors at sites of metastasis would be of great benefit for patients who have advanced cancer. Destroying tumors in bone and also slowing the development of osteolytic lesions would be desirable therapies and greatly improve the prognosis of patients who have bone metastasis," the authors state.

In summary, Mayo Clinic researchers found that 2ME2 could:

* effectively target breast cancer cells

* prevent the spread of breast cancer cells to bone

* protect bone from osteolysis, which is a type of bone metastasis in

which the bone is eaten away by cancer cells.

Although clinical trials of 2ME2 for breast cancer patients have not taken place, other clinical studies of 2ME2 have been conducted. These trials are based on an oral version of 2ME2 to treat primary tumors, but this method has its limitations, as the oral version of 2ME2 is poorly suited to getting into the blood system and reaching tumors. The new Mayo Clinic study resolves this by delivering 2ME2 by injection and in a lower dose -- eight times lower than the comparable oral version used in mouse models.

"We found a complete reduction of tumors in the soft tissue (mammary fat glands) and in tumors in the bone. It targeted and blocked the metastasis f
'/>"/>

SOURCE Mayo Clinic
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... -- Decision Resources Group finds that the markets for peripheral ... Russia , India ... see robust expansion as these economies expand and as ... revenues will be somewhat impeded by poor distribution of ... and demand for low-cost products, the market will ultimately ...
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... and LOS ANGELES , May 10 ... "Company" or,"China Yongxin"), one of the leading health products company ... 2010 , the Company,s subsidiary, Changchun,Yongxin Dirui Medical Co. Inc. ... for Jilin province of China . According,to ...
... May 10 /PRNewswire-Asia/ -- On April 11, ... with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred to ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; NYSE: ... the,China International Economic and Trade Arbitration Commission (CIETAC), which,has recently ...
Cached Medicine Technology:China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 2China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 3Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:10/1/2014)... Chino Hills, CA (PRWEB) October 01, 2014 ... the internationally-franchised Fit Body Boot Camp fitness boot camps, ... selling personal training , with sold out business ... a stint as marketing consultant to a recent Spike ... looming, Keuilian says that now is the time for ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
(Date:10/1/2014)... October 01, 2014 Innovations announces the ... to broadcast on Monday, October 20, 2014 at 7:30 ... Innovations will go behind the scenes to learn about ... segment will explore the practical help and information Break ... teaches the warning signs of abuse, how to navigate ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was ... Martha Stewart American Made Awards (MSAMAs), an annual competition ... in the fields of crafts, design, food and style. ... finalist in the MSAMAs, which celebrates entrepreneurs and artisans ... local communities and changing the way we shop, work ...
(Date:10/1/2014)... October 01, 2014 Dr. Saj Jivraj, ... and prosthodontists, is traveling to Chennai, India, tomorrow to ... Oct. 2 and 3. , Dr. Jivraj is founder ... and Oxnard, Calif., and one of the world’s foremost ... and replacement. He is speaking to the Indian Society ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... Association of Retired Xerox Employees, Inc. (ARXE) has retained ... R. Pfalzgraf, Jr., Esq., and Danielle Shainbrown, Esq.) and ... action against Xerox Corporation, in an effort to maintain ... retirees. , Beginning in 2010, nearly 25 percent of ...
... Sept. 30 Connectyx Technologies Holding Group Inc. (Pink Sheets: ... York, NY as its independent registered public accountant for the ... be provided include auditing and preparation for filing Form 10 ... for Connectyx in order to become a Fully Reporting Company ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced ... SR/zonisamide SR), the Company,s second late stage investigational combination ... efficacy endpoint by demonstrating statistically significantly greater weight loss ... The Company plans to meet with the U.S. ...
... Halloween just around the corner, health-conscious adults and trick-or-treaters ... other snacks that are starting to hit store shelves. ... alternative treat that won,t derail their healthy lifestyles need ... Milk®. , Tiger,s Milk has delivered essential proteins, ...
... , CLAREMONT, Calif., Sept. 30 ... Program (PBPM), scheduled to begin in January 2010, for those ... interested in enhancing their skills before applying to medical school. ... a career as a medical professional," says Sheldon M. Schuster, ...
... BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... China, announced today that,Sinovac has received its second purchase ... Industry and Information Technology of the People,s,Republic of China ... is required to produce an additional 3 million doses ...
Cached Medicine News:Health News:Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 2Health News:Connectyx Technologies Retained the Marcum Group in New York as its Independent Registered Public Accountant for the Purpose of Becoming a Fully Reporting Company 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 3Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 4Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 5Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 6Health News:Have a Healthier Halloween with Tiger's Milk(R) 2Health News:KGI Establishes Post Baccalaureate Premedical Program 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 3
... Philip's EASITrak 12 gives you the detailed ... treatment decisions for your patients with palpitations, ... with the EASI Lead System, this transtelephonic ... to capture a derived 12-lead ECG. Comfortable ...
... Viewer Phonocardiogram (PCG). The ZAC-Viewer is ... to record, condition, display and print heart ... The product acquires and displays the recorded ... sites, and allows user-selectable filtering of each ...
... with the challenge of,controlling costs while ... patient data,management is critical. INFINITY modular,patient ... important clinical information,wherever you are in ... concept,makes your job easier. You can ...
... system is a combination of a Siemens SOMATOM ... AXIOM Multistar angiography unit. Both systems use the ... between floating DSA position and fixed CT position. ... the park position. When it is nesessary to ...
Medicine Products: